Question 1

What does a tesamorelin dosage chart actually contain?

Accepted Answer

One row, if it is honest. The published record runs on a single figure, and a 2016 reimbursement review states it the way the label does: the dosage is 2 mg (two 1 mg vials) injected subcutaneously once a day. There is no titration ladder behind tesamorelin, no weight-based calculation and no second strength in the approved presentation. A chart that shows a range, a starting point and a build-up is describing something other than this compound's published record. What a real chart holds is the study, the population, the amount, the route and the length of exposure, and the second of those columns is the important one, because every figure here belongs to the people who received it. Why the approval reaches only one diagnosis is worked through on the Tesamorelin overview.

Question 2

What amount does the approved label specify?

Accepted Answer

Two milligrams a day, under the skin, as two separate 1 mg vials. The pharmacy arithmetic matches that: the same 2016 review prices a box of 60 vials (30-day supply), which is two vials used each day for a month. A 2011 note records when the schedule entered the record, dating it to November 2010, when tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration. The approval it carries is for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Note the form the figure takes. It is a fixed daily amount rather than a rate per kilogram, so it is not scaled to anybody's body weight, and the label sets out who may receive it rather than how to adjust it.

Question 3

Which patients were given that amount?

Accepted Answer

Adults with HIV, in every trial that published one. In the 2007 programme the investigators randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat. A 2010 report covers a 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy. The 2019 liver trial required people with HIV infection and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy. The one exception was a 2014 trial in 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests, and it measured a scan parameter rather than body fat. That is the whole population behind the figure, and an amount set against a diagnosis, under supervision, with material of a known strength, describes the people who received it and nobody else.

Question 4

Does the labelled amount apply to a research-grade vial?

Accepted Answer

No, and this is the sentence the rest of the page exists to support. The approved schedule is written for one specific injection: two 1 mg vials of material made to a filed specification, dispensed against a diagnosis, in a 60-vial box. A vial bought outside that supply carries a name and a number that nothing among these sources has verified. The FDA enforcement file shows how far the presentations diverge. One compounded entry reads Tesamorelin, 1mg/vial, 6mL vial, Lyophilized Powder for Reconstitution and Subcutaneous Injection. Another reads Tesamorelin for Injection, 15mg, 10 mL Multi-Dose Vial. Lyophilized means freeze-dried, and a 15 mg multi-dose container is not a form the approved schedule was ever written against, so applying a labelled daily amount to it is arithmetic on an unverified strength rather than a dose. We do not publish that step, because none of the studies covered here has validated it.

Question 5

What amounts did the published trials assign?

Accepted Answer

The same one, every time. In the 2007 trial participants received a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks. The 2010 trial assigned tesamorelin [2 mg subcutaneous (SC) every day] or placebo in a 2:1 ratio. The 2019 liver trial assigned people to receive either tesamorelin 2 mg once daily or placebo once daily for 12 months. In the 2025 cognition trial, seventy-three participants were randomized 3:2 to tesamorelin or SOC (2 mg subcutaneously daily), where SOC means standard of care. A 2026 systematic review pooling the field reports its results for Tesamorelin 2mg rather than for a range of amounts. Across all of those the figure is identical, only the length of exposure and the outcome measured differ, and there is nothing to titrate and no second number anywhere in the published record.

Question 6

How was it injected, and how often?

Accepted Answer

Subcutaneously, once a day, every day, in every protocol among these sources. The label itself specifies injected subcutaneously once a day, and the trials match it, with a 2008 report describing treatment of HIV patients with daily tesamorelin for 26 weeks. Subcutaneous means into the fat layer under the skin rather than into a muscle or a vein. Nothing among these sources tested a different route, a different interval or a split daily amount, so there is no comparison to report between a daily schedule and a less frequent one. What the daily interval reflects is the design of the compound, since a 2011 review describes it as an analogue that stimulates the synthesis and release of endogenous growth hormone rather than supplying the hormone itself. Read a daily schedule as what was studied and not as what was optimised, because no trial covered here set one interval against another.

Question 7

How long did the published courses run?

Accepted Answer

Twenty-six weeks is the base unit and a year is the ceiling. The 2010 programme ran twelve months in two phases, with patients re-randomised halfway: in the extension phase (months 6-12), patients receiving tesamorelin were rerandomized to continue on tesamorelin (2 mg SC every day) or switch to placebo. The 2008 extension reports that the change in VAT was sustained at -18% over 52 weeks of treatment, then states the limit of its own result, that though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment. A 2026 protocol proposes a further design, randomising participants for 24 weeks, followed by a 24-week extension phase of independent exercise, and it has not reported. So published exposure stops at a year, and the schedule is a continuing one rather than a course anybody finishes.

Question 8

How much bacteriostatic water goes into a tesamorelin vial?

Accepted Answer

None of the sources covered here states a diluent volume, and that absence is informative rather than inconvenient. What they state is a strength per vial, which is the number the arithmetic actually needs. The approved presentation supplies two 1 mg vials a day out of a box of 60 vials (30-day supply). The compounded entries on the FDA record are different objects again, one of them a 1mg/vial, 6mL vial and the other a 15mg, 10 mL Multi-Dose Vial. Concentration follows from the strength in the vial divided by the volume added, so a diluent figure is chosen by whoever reconstitutes it rather than fixed by the compound. The arithmetic itself runs at the reconstitution calculator, on numbers a reader supplies. What no figure here can supply is confidence that the strength printed on an unapproved vial is the strength inside it.

Question 9

How long does a 5 mg vial last?

Accepted Answer

That question has no answer in the approved record, because 5 mg is not an approved presentation. The label supply is built from 1 mg vials, sold as a box of 60 vials (30-day supply), which is two vials a day for a month. The FDA enforcement file holds compounded tesamorelin as a 1mg/vial, 6mL vial and as a 15mg, 10 mL Multi-Dose Vial, and neither of those matches the approved presentation either. So a 5 mg vial is a market object rather than a labelled one, and dividing its printed strength by a labelled daily amount is arithmetic on two numbers that were never written for each other. We do not publish that division, because the number on the vial is a claim made by whoever filled it and nothing among the sources covered here has measured the contents of one.

Question 10

What do these records say about storage and expiry?

Accepted Answer

One line, and it comes from a recall rather than from a trial. A Kentucky compounder's tesamorelin was withdrawn in 2018 because the vial indicates a 1 year expiration date instead of a 6 month expiration date. That is a statement about the shelf life of a sealed powder, not about what happens after it is mixed. The second recall, from 2025, covers a multi-dose container pulled for lack of assurance of sterility, which is a question about whether the contents stayed clean between filling and use. Nothing among these sources states a refrigeration rule, a window after reconstitution or a beyond-use date for compounded material. Read the pair together, because the two things the FDA actually caught on this compound were a date printed wrong and sterility that could not be assured, and both of those are handling questions rather than potency ones.

Question 11

Is there a published amount for body composition outside HIV?

Accepted Answer

Not among the sources covered here. A 2012 review states the position directly, recording that limited data support off-label uses of tesamorelin at this time. A 2026 primer written for sports medicine physicians goes further on the uses people ask about. It notes that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. It adds that across the compounds it reviewed, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. The one trial outside HIV used the same daily figure in 39 obese adults with low growth hormone output. Its endpoint was a scan reading of muscle energy recovery rather than fat. So the labelled amount exists for one use, and nothing among these sources sets it for a second. An approval for one use is not a licence for another, and a figure lifted across that line stops being a regulatory fact the moment it crosses.

Question 12

Is there a tesamorelin cycle?

Accepted Answer

Not in the published protocols, which run continuously for as long as a trial lasts. The nearest thing to a cycle in this record is a deliberate withdrawal, since in the 2010 extension patients receiving tesamorelin were rerandomized to continue on tesamorelin or switch to placebo. What that arm found is the reason cycling is the wrong frame here. A 2011 review records that discontinuation of therapy during this period resulted in the reaccumulation of VAT, and the 2008 extension states that these effects do not last beyond the duration of treatment. So stopping is not a rest phase that preserves a gain, and among these sources it is the point at which the measured change starts going back. That makes the labelled schedule an ongoing one, and the amounts on this page describe a continuing course inside one diagnosis rather than a block of weeks anybody finishes. What those same trials recorded going wrong is catalogued at the Tesamorelin safety page.

Trial	Amount assigned	Compared against
2007 trial, 26 weeks	2 mg daily, under the skin	Placebo
2010 trial	2 mg daily, under the skin	Placebo, 2:1
2019 liver trial, 12 months	2 mg once daily	Placebo
2025 cognition trial	2 mg daily, under the skin	Standard of care, 3:2

Tesamorelin protocols in the published literature